ArticleNPJ breast cancer2025

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Mengqian Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.